Strategies and Advances in Site-Specific Integration of Exogenous Large Genes
Human Gene Therapy · 01.07.2026 · 37 (13-14) · 551-565
DOI: 10.1177/10430342261445050 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Gene Therapy, online erschienen am 24.04.2026. Verfasst von Zhencheng Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Biosciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, P.R. China. Hauptthemen laut MEDLINE: Gene Editing, Genetic Therapy, Mutagenesis, Insertional. Die Arbeit nennt 53 Literaturangaben.
Abstract (Originalsprache)
Large genomic deletions (≥1 kb) are a recurrent class of disease-causing lesions in monogenic disorders, frequently leading to complete gene inactivation or the loss of critical cis-regulatory elements. Addressing these defects in a therapeutically relevant manner requires integration modalities capable of delivering and stably installing large exogenous DNA sequences at predefined genomic loci with an improved safety profile. By contrast, legacy approaches—including viral-vector delivery, recombinase-based strategies, and transposon-mediated insertion—typically achieve integration through random or semi-random mechanisms, which, despite their practicality and often favorable efficiencies, limit control over insertion site and copy number and may increase the risk of insertional mutagenesis and position-dependent variability in transgene expression. The past few years have witnessed rapid methodological diversification driven by genome editing, resulting in a growing repertoire of locus-specific strategies for large-fragment DNA insertion that are reshaping both disease-model construction and genetic therapeutics. In this Review, we synthesize the main classes of targeted large-fragment integration technologies reported to date. We begin with homology-directed repair (HDR)-dependent CRISPR-Cas9 knock-in strategies and discuss how donor architecture and local donor recruitment can be leveraged to improve integration outcomes for kilobase-scale payloads. We then examine approaches centered on prime editing, particularly those that couple prime editing with engineered serine/tyrosine recombinases to support programmable insertion of large DNA cargos. We close by surveying emerging HDR-independent systems based on CRISPR-guided transposition and retrotransposition, and we provide a comparative perspective on their performance envelopes, constraints, and trajectories toward broader biomedical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biosciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, P.R. China.
- College of medical information engineering, Guangdong Pharmaceutical University, Guangzhou, P.R. China.
ORCID-Profile: Wenfeng Zhang
Zitieren
APA
Wu, Z., Chen, J., Huang, M., Hu, W., Liu, Y., Shao, H., & Zhang, W. (2026). Strategies and Advances in Site-Specific Integration of Exogenous Large Genes. Human Gene Therapy, 37(13-14), 551-565. https://doi.org/10.1177/10430342261445050
Vancouver
Wu Z, Chen J, Huang M, Hu W, Liu Y, Shao H, et al. Strategies and Advances in Site-Specific Integration of Exogenous Large Genes. Human Gene Therapy. 2026;37(13-14):551-565. doi:10.1177/10430342261445050
BibTeX
@article{Wu2026,
author = {Wu, Zhencheng and Chen, Jia and Huang, Manqi and Hu, Wenqi and Liu, Yiyu and Shao, Hongwei and Zhang, Wenfeng},
title = {Strategies and Advances in Site-Specific Integration of Exogenous Large Genes},
journal = {Human Gene Therapy},
year = {2026},
volume = {37},
number = {13-14},
pages = {551--565},
doi = {10.1177/10430342261445050}
}
EUVIMED